BL-B01D1-LUNG-101: Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

http://clinicaltrials.gov/ct2/show/NCT05983432

Sep 22, 2026